Initial Double Sequential External Defibrillation in Out of Hospital Cardiac Arrest
Launched by ST. OLAVS HOSPITAL · Oct 31, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The DUALDEFIB trial is studying a new approach to treating patients who experience cardiac arrest outside of a hospital, specifically when their heart is in a dangerous rhythm called refractory ventricular fibrillation (rVF). This trial will explore whether using two defibrillators at the same time, known as Double Sequential External Defibrillation (DSED), as the first treatment can improve chances of survival and lead to better brain function compared to the standard method, which usually involves trying one defibrillator multiple times before switching to the new method.
To be eligible for this trial, participants must be adults aged 18 and older who have suffered a cardiac arrest and are found to have a shockable heart rhythm. However, those who are pregnant, incarcerated, or have a do-not-resuscitate order are not eligible to participate. The trial is not yet recruiting participants, but it aims to learn more about the potential benefits of starting treatment with DSED right away, which could make a significant difference in outcomes for patients experiencing cardiac arrest.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with out of hospital cardiac arrest presenting with a shockable rhythm
- Exclusion Criteria:
- • Age below 18 years
- • Obvious or suspected pregnancy
- • Incarcerated patients
- • Preexisting do-not-resuscitate order
About St. Olavs Hospital
St. Olavs Hospital is a leading healthcare institution located in Trondheim, Norway, renowned for its commitment to advancing medical research and improving patient care. As a key clinical trial sponsor, the hospital is dedicated to conducting innovative research across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With state-of-the-art facilities and a patient-centric approach, St. Olavs Hospital aims to enhance clinical outcomes and contribute to the global body of medical knowledge through rigorous and ethically conducted clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Trial Officials
Kjetil Karlsen
Study Director
St. Olavs Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported